News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
590,895 Results
Type
Article (52065)
Company Profile (133)
Press Release (538687)
Multimedia
Podcasts (135)
Webinars (20)
Section
Business (156567)
Career Advice (2469)
Deals (29228)
Drug Delivery (137)
Drug Development (71926)
Employer Resources (159)
FDA (16135)
Job Trends (12666)
News (281397)
Policy (30842)
Tag
Academia (2670)
Academic (1)
Accelerated approval (27)
Adcomms (35)
Allergies (127)
Alliances (40185)
ALS (158)
Alzheimer's disease (1761)
Antibody-drug conjugate (ADC) (276)
Approvals (16225)
Artificial intelligence (471)
Autoimmune disease (127)
Automation (28)
Bankruptcy (319)
Best Places to Work (9735)
BIOSECURE Act (23)
Biosimilars (179)
Biotechnology (80)
Bladder cancer (148)
Brain cancer (55)
Breast cancer (575)
Cancer (4331)
Cardiovascular disease (378)
Career advice (2088)
Career pathing (38)
CAR-T (264)
CDC (59)
Cell therapy (696)
Cervical cancer (35)
Clinical research (61031)
Collaboration (1385)
Company closure (4)
Compensation (1040)
Complete response letters (64)
COVID-19 (2765)
CRISPR (85)
C-suite (665)
Cystic fibrosis (137)
Data (5468)
Decentralized trials (2)
Denatured (31)
Depression (126)
Diabetes (455)
Diagnostics (5886)
Digital health (35)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (204)
Drug pricing (200)
Drug shortages (35)
Duchenne muscular dystrophy (221)
Earnings (63693)
Editorial (60)
Employer branding (20)
Employer resources (144)
Events (87300)
Executive appointments (884)
FDA (18887)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1265)
Gene editing (184)
Generative AI (40)
Gene therapy (574)
GLP-1 (1016)
Government (4323)
Grass and pollen (8)
Guidances (372)
Healthcare (16138)
HIV (49)
Huntington's disease (44)
IgA nephropathy (78)
Immunology and inflammation (266)
Immuno-oncology (40)
Indications (69)
Infectious disease (3008)
Inflammatory bowel disease (181)
Inflation Reduction Act (13)
Influenza (99)
Intellectual property (203)
Interviews (455)
IPO (14514)
IRA (56)
Job creations (3266)
Job search strategy (1717)
Kidney cancer (16)
Labor market (75)
Layoffs (612)
Leadership (38)
Legal (7248)
Liver cancer (89)
Longevity (12)
Lung cancer (589)
Lymphoma (346)
Machine learning (36)
Management (54)
Manufacturing (644)
MASH (162)
Medical device (11965)
Medtech (11996)
Mergers & acquisitions (15633)
Metabolic disorders (1219)
Multiple sclerosis (138)
NASH (22)
Neurodegenerative disease (307)
Neuropsychiatric disorders (83)
Neuroscience (2880)
NextGen: Class of 2025 (5369)
Non-profit (3771)
Now hiring (31)
Obesity (596)
Opinion (284)
Ovarian cancer (148)
Pain (178)
Pancreatic cancer (190)
Parkinson's disease (257)
Partnered (26)
Patents (435)
Patient recruitment (382)
Peanut (54)
People (48152)
Pharmaceutical (37)
Pharmacy benefit managers (29)
Phase I (18540)
Phase II (26505)
Phase III (21216)
Pipeline (3741)
Policy (311)
Postmarket research (2335)
Preclinical (7737)
Press Release (38)
Prostate cancer (219)
Psychedelics (50)
Radiopharmaceuticals (246)
Rare diseases (777)
Real estate (4721)
Recruiting (65)
Regulatory (23273)
Reports (39)
Research institute (2525)
Resumes & cover letters (410)
Rett syndrome (24)
RNA editing (13)
RSV (72)
Schizophrenia (142)
Series A (209)
Series B (157)
Service/supplier (9)
Sickle cell disease (95)
Special edition (24)
Spinal muscular atrophy (142)
Sponsored (45)
Startups (3075)
State (1)
Stomach cancer (19)
Supply chain (101)
Tariffs (97)
The Weekly (103)
Vaccines (1062)
Venture capital (80)
Weight loss (422)
Women's health (62)
Worklife (21)
Date
Today (102)
Last 7 days (554)
Last 30 days (2273)
Last 365 days (29323)
2025 (28834)
2024 (32640)
2023 (36457)
2022 (46795)
2021 (50506)
2020 (47767)
2019 (38964)
2018 (29490)
2017 (29383)
2016 (27842)
2015 (30549)
2014 (24106)
2013 (19975)
2012 (21312)
2011 (21661)
2010 (19655)
Location
Africa (745)
Alabama (70)
Alaska (6)
Arizona (231)
Arkansas (11)
Asia (34953)
Australia (6264)
California (9811)
Canada (2501)
China (844)
Colorado (384)
Connecticut (437)
Delaware (302)
Europe (84168)
Florida (1490)
Georgia (303)
Hawaii (3)
Idaho (44)
Illinois (700)
India (47)
Indiana (456)
Iowa (21)
Japan (360)
Kansas (106)
Kentucky (29)
Louisiana (19)
Maine (74)
Maryland (1263)
Massachusetts (7141)
Michigan (253)
Minnesota (531)
Mississippi (5)
Missouri (114)
Montana (17)
Nebraska (21)
Nevada (107)
New Hampshire (66)
New Jersey (2675)
New Mexico (19)
New York (2604)
North Carolina (1297)
North Dakota (8)
Northern California (4762)
Ohio (274)
Oklahoma (16)
Oregon (34)
Pennsylvania (1944)
Puerto Rico (14)
Rhode Island (33)
South America (1109)
South Carolina (57)
South Dakota (1)
Southern California (3803)
Tennessee (145)
Texas (1489)
United States (34881)
Utah (269)
Vermont (1)
Virginia (230)
Washington D.C. (76)
Washington State (790)
West Virginia (4)
Wisconsin (97)
Wyoming (1)
590,895 Results for "banner alzheimer s institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
I Remember Aduhelm. The Return of Roche in Alzheimer’s Is a Turning Point
After covering the Alzheimer’s space through every high and low,
BioSpace
’s Annalee Armstrong welcomes back Roche for the 2026 Alzheimer’s Renaissance.
December 2, 2025
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
November 24, 2025
·
3 min read
·
Heather McKenzie
Podcast
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the 2025 Clinical Trials on Alzheimer’s Disease conference continues following two disappointing readouts; and Novo Nordisk’s amycretin yields promising weight loss results.
December 3, 2025
·
1 min read
·
Heather McKenzie
Alzheimer’s disease
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau antibody failed to slow clinical decline in patients with early Alzheimer’s disease.
November 24, 2025
·
1 min read
·
Heather McKenzie
Earnings
As Biogen Nears Presymptomatic Alzheimer’s Readout for Leqembi, Can Doctors Be Convinced?
To expand the population for the anti-amyloid Alzheimer’s drugs, Lilly and Biogen are testing presymptomatic patients. Will doctors be open to this paradigm-shifting change?
October 30, 2025
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
Roche, Lilly Win First FDA Nod for Alzheimer’s Blood Test for Primary Care Use
Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s Eisai-partnered Leqembi, with CEO Chris Viehbacher recently noting that such biomarker-based tests could “remove some of the bottlenecks” in uptake.
October 14, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
5 Alzheimer’s Readouts To Watch
These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up novel pathways of action to treat the memory-robbing illness.
July 28, 2025
·
8 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen, Eisai’s Leqembi Slows Alzheimer’s Progression Through 4 Years of Treatment
Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the earlier stages of Alzheimer’s disease as compared to the condition’s natural progression.
July 30, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10%
“We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday.
November 24, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
December 2, 2025
·
8 min read
1 of 59,090
Next
